ClinicalTrials.gg
Active, not recruitingNCT07565831Updated May 4, 2026

Study on the Prediction of Regional Lymph Node Metastasis in Colorectal Cancer by Spectral CT Combined With MSI

An interventional study of Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes. in Colo-rectal Cancer, sponsored by Yunnan Cancer Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Yunnan Cancer Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Planned enrollment
55th of 163
260 · median 110
Started
2025
with 17 others
No phase
50 of 211
23 open now
Primary completion
2026-12
later than 61 of 116 live
Registered
201st of 211
by date

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 55th largest by planned enrollment of the 163 interventional ones that give a count, is one of 18 that started in 2025, is one of 50 with no phase, reaches primary completion later than 61 of the 116 other live ones, and was the 201st registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

03

Conditions studied

  • Colo-rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Undergo contrast-enhanced Quark energy spectral CT examination of the lower abdomen/pelvis within 1 week before treatment;(2) MSI status confirmed;(3) Age >18 years;(4) Patients with suspected colorectal cancer;(5) Patients who provided .

Exclusion criteria

Exclusion Criteria:

  • (1) Severe cardiac, pulmonary, or renal insufficiency;(2) Allergy to iodine-based contrast agents;(3) Inability to cooperate during the CT examination;(5) Poor image quality from Quark spectral CT scans;(6) Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Study on the prediction of regional lymph node metastasis in colorectal cancer by spectral CT combin

    Prospectively collect medical images and clinical data related to colorectal cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accuratestaging of colorectal cancer. Patientsdiagnosed with colorectal cancer in Yunnan Provincial Cancer Hospital from August 2025 to December 2026 were consecutively included,and after scanning with Philips Quark CT, the TNM stage of colorectal cancer patients was assessed by two radiologists, and finally statistical analysis was performed

    Diagnostic Test: Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes.

Interventions

  • Diagnostic testInvestigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes.

    The CT scan is part of the standard treatment protocol.

06

What researchers measure

Primary outcomes

  1. Pathological TNM staging

    Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

    Time frame: 1 day

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 16 months is below that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Aug 4, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07565831
Lead sponsor
Yunnan Cancer Hospital
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Aug 4, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 4, 2026

Study contacts

Lianhua Ye
study director · Ethics Committee of Yunnan Provincial Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion